This, depending on cellular p53 status, activates either RP–Mdm2–p53 pathway leading to the cell cycle arrest in p53-proficient non-transformed cells or ATR–ChkL–γH2Ax axis leading to the death of p53-deficient cancer cells (Dong et al. 2017). This evidence concerns the gene TP53 and cancer.